228 related articles for article (PubMed ID: 20022093)
1. RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.
Zhao Y; Zong ZH; Xu HM
Gynecol Oncol; 2010 Mar; 116(3):563-71. PubMed ID: 20022093
[TBL] [Abstract][Full Text] [Related]
2. Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2.
Zhang A; Meng L; Wang Q; Xi L; Chen G; Wang S; Zhou J; Lu Y; Ma D
Oncol Rep; 2006 Apr; 15(4):831-6. PubMed ID: 16525667
[TBL] [Abstract][Full Text] [Related]
3. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
Wang P; Wu X; Chen W; Liu J; Wang X
Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312
[TBL] [Abstract][Full Text] [Related]
4. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer.
Hata K; Nakayama K; Fujiwaki R; Katabuchi H; Okamura H; Miyazaki K
Gynecol Oncol; 2004 Apr; 93(1):215-22. PubMed ID: 15047239
[TBL] [Abstract][Full Text] [Related]
5. [Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma].
Shi HR; Song WJ; Chen ZM; Wu QH
Ai Zheng; 2005 Sep; 24(9):1127-31. PubMed ID: 16159439
[TBL] [Abstract][Full Text] [Related]
6. [Expressions of TGIF, MMP9 and VEGF proteins and their clinicopathological relationship in gastric cancer].
Hu ZL; Wen JF; Shen M; Liu Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 31(1):70-4. PubMed ID: 16562680
[TBL] [Abstract][Full Text] [Related]
7. Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer.
Campos X; Muñoz Y; Selman A; Yazigi R; Moyano L; Weinstein-Oppenheimer C; Lara HE; Romero C
Gynecol Oncol; 2007 Jan; 104(1):168-75. PubMed ID: 16935322
[TBL] [Abstract][Full Text] [Related]
8. [Inhibitory effects of RNA interference on expression of matrix metalloproteinase-9 gene and invasiveness and adhesion in ovarian cancer cells].
Hu XX; Li L; Li DR; Zhang W; Tang BJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):579-83. PubMed ID: 17181964
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
10. [Role of vascular endothelial growth factor overexpression in ovarian tumor invasion and mechanism].
Lu Y; Zhang A; Wang S; Li J; Wang C; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):294-7. PubMed ID: 12133405
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.
Hata K; Osaki M; Dhar DK; Nakayama K; Fujiwaki R; Ito H; Nagasue N; Miyazaki K
Cancer Chemother Pharmacol; 2004 Jan; 53(1):68-74. PubMed ID: 14569416
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9.
Cheung LW; Leung PC; Wong AS
Cancer Res; 2006 Nov; 66(22):10902-10. PubMed ID: 17108127
[TBL] [Abstract][Full Text] [Related]
13. Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor.
Zhou J; Gan N; Zhang W; Lu W; Xie X
J Obstet Gynaecol Res; 2010 Apr; 36(2):232-8. PubMed ID: 20492371
[TBL] [Abstract][Full Text] [Related]
14. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia up-regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells.
Zhu G; Saed GM; Deppe G; Diamond MP; Munkarah AR
Gynecol Oncol; 2004 Aug; 94(2):422-6. PubMed ID: 15297183
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer.
Stimpfl M; Tong D; Fasching B; Schuster E; Obermair A; Leodolter S; Zeillinger R
Clin Cancer Res; 2002 Jul; 8(7):2253-9. PubMed ID: 12114428
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas.
Ueda M; Hung YC; Terai Y; Kanda K; Kanemura M; Futakuchi H; Yamaguchi H; Akise D; Yasuda M; Ueki M
Clin Cancer Res; 2005 May; 11(9):3225-32. PubMed ID: 15867217
[TBL] [Abstract][Full Text] [Related]
18. [Correlation of expression of RhoA (RhoC and their effector ROCK-1 with malignant phenotype of ovarian cancer cells in vitro].
Han ZQ; Zhang AL; Wu MF; Liu YL; Chen G; Li FJ; Gao QL; Liao GN; Lu YP; Wang SX; Ma D
Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):385-8. PubMed ID: 15355639
[TBL] [Abstract][Full Text] [Related]
19. The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.
Zhao Y; Zheng HC; Chen S; Gou WF; Xiao LJ; Niu ZF
Gynecol Oncol; 2013 Sep; 130(3):570-8. PubMed ID: 23764197
[TBL] [Abstract][Full Text] [Related]
20. The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor.
Tsuchiya T; Nakahama K; Asakawa Y; Maemura T; Tanaka M; Takeda S; Morita M; Morita I
Gynecol Endocrinol; 2009 Feb; 25(2):104-9. PubMed ID: 19253105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
